Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to rosuvastatin or add ezetimibe versus uptitrate atorvastatin in high-risk hypercholesterolemia
2004-000959-42Phase 4Completed
- Sponsor
- Integrated Therapeutics Group
- Start
- Jul 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hypercholesterolemia comparing Rosuvastatin switch, Ezetimibe add-on to atorvastatin 10 mg and Atorvastatin dose escalation to 20 mg (3 arms). Primary endpoints: Change in LDL cholesterol from baseline to weeks 5 and 6, Difference in LDL cholesterol lowering from baseline to study end and 1 more. Started Jul 2004; status: completed.
02
Drugs
ezetimiberosuvastatinatorvastatin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2004-000959-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000959-42.